February #32 : Déjà Vu

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Marked Man

Warts and All

Cracker Jack

Names Will Never Hurt You?

War on the Warts

Rub a Drug Flub

Déjà Vu

Green Means Go

The Cutting Edge

Sealed w/KS

Shalala Infections

An Ad Is an Ad Is an Ad

ADAP Tapped

Trojan Wars

Girls on Trial

The Pill Drill

Say What

Tapped for Greatness

My Brother

Honey, Mud, Maggots, and Other Medical Marvels

Carmine’s Story

There Is Hope: Learning to Live With HIV

Crocodile Tears

The Kinsey Sicks

Gridlock’d

CATIE

Cocktails: The Morning After

Patrolling the Borders

AIDSpeak

Instruments of Infection

Hiccup Blues

A New Kind of Waisting

.38 Caliber

The Labors for Your Fruits

Barbed Comments

Party Planner

Hollywood Golightly

At the End of My Hope

Criminal Body

I Got All My Sistahs With Me

Primo Chemo

S.O.S.

Mailbox

POZ Stars

OBITS



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

February 1998

Déjà Vu

A dual to the start

Whose standard of care is bigger? It’s a draw. The HIV treatment guidelines put out by the U.S. Department of Health and Human Services (HHS) and the U.S. branch of the International AIDS Society (IAS) are virtually identical: Both push a protease-based three-drug combo and advise that most HIVers with no symptoms delay therapy, particularly those who can’t adhere to pain-in-the-butt regimens. The major difference involves when to start treatment: HHS recommends it when one’s viral load exceeds 10,000 to 20,000 copies/mL or when one’s CD4 count is less than 500; the more-aggressive IAS says 5,000 to 10,000, regardless of CD4s. Why the difference? Check out the membership on the two panels: Although the usual AIDS suspects had a hand in drafting both guidelines, the IAS was a doctors-only affair, while the feds featured not only docs, researchers and industry reps but activists and PWAs, many of whom are skeptical of early intervention.

The difference may be so much hair-splitting. “The guidelines disagree in an area where nobody has the absolute answer, so it comes down to expert opinion,” said Project Inform’s Martin Delaney, an HHS panel member. He and others doubt the need for the redundancy and question the rules’ timeliness. “We don’t need two sets, and a lot of it is out of date,” he said. “They make a religious issue out of everyone having to be on two nucleosides and one protease, but now we’re looking at more powerful two-drug combos.”


Search: HIV treatment guidelines, U.S. Department of Health and Human Services, HHS, International AIDS Society, IAS




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    newlife202
    JOLIET
    Illinois


    Heartland4now
    Tacoma
    Washington


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Will decriminalizing injection drug use help end the global HIV epidemic?
Yes
No

Survey
PrEP Course

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.